Tag: drug

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today announced the results of its annual meeting of shareholders held on June 9, 2026 (the “Meeting”). Common shareholders at the Meeting affirmatively approved the following resolutions:

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham 

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

June 9, 2026
Announcement no. 12

BASEL, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- FloBiotech today announced an agreement with UCLA Health to advance a novel class of therapeutics targeting biologically validated protective pathways in neurodegeneration.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billion in 2024 and is expected to reach USD 519.11 Billion in 2025 and is expected to reach around USD 926.54 Billion by 2034, at a CAGR of 6.55% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Alkem Laboratories Limited, Teva Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Lupin Limited, STADA Arzneimittel AG, Hikma Pharmaceuticals plc, Torrent Pharmaceuticals Ltd., Endo International plc, Aurobindo Pharma Limited, Sawai Pharmaceutical Co. Ltd., Mallinckrodt plc, Amneal Pharmaceuticals Inc and others.